Profile of patients treated with omalizumab in routine clinical practice in Spain
Allergol. immunopatol
; 42(2): 102-108, mar.-abr. 2014. tab, graf
Article
in English
| IBECS
| ID: ibc-121007
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
BACKGROUND:
Omalizumab is indicated in patients with severe allergic asthma not controlled by high-dose inhaled glucocorticoids and long-acting beta-agonists. Few data are available on the profile of patients treated with this drug in routine clinical practice in Spain.OBJECTIVE:
To describe the profile of patients with severe allergic asthma treated with omalizumab and the course of the disease after a period of treatment.METHODS:
Retrospective, multicentre study, recording the data on patients of either sex and ≥12 years with uncontrolled severe allergic asthma, previously treated with omalizumab. Data were evaluated in relation to pulmonary function, symptoms, quality of life, and concomitant anti-asthma treatment before the prescription of omalizumab and at the time of the study visit.RESULTS:
214 patients were evaluable (mean age = 48.2 ± 17.7 years; mean age at the time of diagnosis = 26.6 ± 16.5 years). 90.7% had experienced exacerbations the year before receiving omalizumab, and the mean total IgE level was 273 ± 205.4 IU/ml. The mean monthly dose was 380.5 ± 185.4 mg. Compared with the baseline situation, differences were observed after treatment with omalizumab in mean FEV1 (62.7 ± 15.9% vs. 70.8 ± 18.7%), in the proportion of patients requiring oral corticosteroids (47.7% vs. 14.0%), and in the ACQ and AQLQ scores. 32.7% of the patients received doses not recommended by the Summary of Product Characteristics (SPC).CONCLUSIONS:
Profile of asthmatic patients treated with omalizumab predominantly corresponds to uncontrolled severe asthma cases, in accordance with SPC's indications. The results of the study suggest a favourable clinical course similar to that observed in other studiesRESUMEN
No disponible
Search on Google
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Asthma
/
Hypersensitivity, Immediate
/
Antibodies, Monoclonal
Type of study:
Controlled clinical trial
/
Observational study
Aspects:
Patient-preference
Limits:
Humans
Language:
English
Journal:
Allergol. immunopatol
Year:
2014
Document type:
Article
Institution/Affiliation country:
Hospital Central de la Defensa/Spain
/
Hospital Clínic/Spain
/
Hospital Universitario Central de Asturias/Spain
/
Hospital de la Princesa/Spain
/
Novartis farmacéutica S.A. Barcelona/Spain